Introduction
Melanoma is the most aggressive form of skin cancer in the world and accounts for over 75% of skin cancer-related deaths. 1 As with many serious cancers, melanoma has a good prognosis when detected in its early stages. 2 Malignant cells often overexpress characteristic receptors on their cell surfaces when compared to normal cells, [3] [4] [5] affording a potential means of detection. For example, the melanocortin 1 receptor, a Gprotein coupled receptor (GPCR), is overexpressed in most forms of melanoma. 6, 7 Among other research groups, [8] [9] [10] we are pursuing detection strategies that employ multivalent interactions by two or more weakly binding ligands attached to a scaffold. Such multivalent molecules can selectively bind with high avidity to cells overexpressing the targeted ligand receptors. [11] [12] Factors that can influence the interactions of multivalent molecules with cell surface receptors include the potency of the ligands utilized, the inter-ligand distances, and the possible geometries of ligand display permitted by the scaffold. Peptide ligands that are known to bind to melanocortin receptors include Ac-Ser-Tyr-Ser-Nle-Glu-His-DPhe-Arg-Trp-Gly-LysPro-Val-NH 2 (1, NDP-α-MSH, high affinity), 13 Ser-Nle-GluHis-DPhe-Arg-Trp-NH 2 (2, MSH(7), medium affinity), 14 and His-DPhe-Arg-Trp-NH 2 (3, MSH(4), low affinity).
14 Because cooperative binding leading to enhanced avidity is more evident when weakly binding ligands are utilized, 11, 12 we (and others [15] [16] [17] [18] [19] ) have used MSH(4) in our multivalent constructs. Control of ligand number, spacing, and geometry depends on the scaffold used to display the MSH(4) ligand. In the absence of crystallographic data on the melanocortin receptors, a homology model based on the crystal structure of the GPCR rhodopsin suggested distances ranging from 20-50 Å between the binding sites of abutted receptors. 20 In previous articles, we described multivalent constructs based on linear [21] [22] [23] [24] and spherical 25 scaffolds, typically with ligand spacing in this range. Using a competitive binding assay and a human embryonic kidney cell line, HEK293, genetically engineered to overexpress the human melanocortin 4 receptor (hMC4R), 9 these constructs were shown to exhibit enhanced binding consistent with statistical effects, but inconsistent with simultaneous binding of two or more ligands to receptors on the cell surface.
Recently, multivalent binding of molecules that incorporate MSH(4) ligands was demonstrated using mono-, di-, and trivalent compounds 4-6. 18 The divalent and trivalent constructs 5 and 6 exhibited 16-fold and 350-fold enhancements, respectively, in the measured IC 50 values compared to the monovalent construct 4 in a competitive binding assay against an NDP-α-MSH-based fluorescent probe. The inter-ligand distances in 5 and 6 were estimated to be 24 ± 5 Å by molecular modeling. Structurally related dendrimeric constructs bearing six or nine MSH(4) ligands exhibited somewhat reduced inhibitory potencies. 19 These studies strongly suggest that narrow limits on ligand spacing exist for observation of true multivalent binding to hMC4 receptors, at least for the engineered HEK293 cell line used in the competitive binding assays.
In light of these observations, we wished to more fully evaluate the effects of ligand spacing and orientation on avidity while simplifying the scaffold to enhance the economy and versatility of the synthetic approach to useful multivalent molecules. In this article, we present syntheses and bioassay results from MSH(4)-bearing multivalent molecules based on phloroglucinol (7), tripropargylamine (8) , and 1,4,7-triazacyclononane (9) scaffold cores. As a part of this study, we also describe new protocols that improve the signal-to-noise ratio for in vitro binding assays when using the engineered HEK293 cells.
Results
Chemistry. Commercially available phloroglucinol (7) was alkylated according to a reported method 26 to produce trisalkyne 10 (Scheme 1). Using microwave-assisted coppercatalyzed azide-alkyne cycloaddition (CuAAC) reactions, the known serinamide azide 11 24 was attached to the phloroglucinol-derived hub, leading to 12a-c. CuAAC reactions of 12b, 12c, and 10 with the known MSH(4) azide 13 24 afforded mono-, bis-, and tris-MSH(4) constructs 14a-c, respectively. Although the reaction vials and solvents were purged with argon to exclude oxygen from the system, if air is introduced during handling oxidation of the reactive Cu(I) species can occur. We observed that inclusion of sodium ascorbate in the reaction mixtures enhanced the repeatability of the product yields.
Serinamide-containing constructs 15a-c were prepared from commercially available tripropargylamine (8) and azide 11 in a similar manner (Scheme 2). However, CuAAC reactions of 15b, 15c, and 8 with MSH(4) azide 13 under the conditions used to prepare 14a-c were unsatisfactory. For the synthesis of 16a and 16b, acceptable yields were obtained when tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) was omitted from the reaction mixture. Normally TBTA stabilizes Cu(I), 27 but in these reactions the product triazoles might serve this function. Along with added TBTA, the products might complex Cu(I) ions, reducing the reaction rate. Reaction of 8 with azide 13 to produce 16c was more challenging. Microwave-assisted reactions with different reagent compositions, solvents, and reaction times failed. However, reaction of 8 with azide 13 in the presence of tetrakis(acetonitrile)copper(I) hexafluorophosphate (TACP) catalyst and 2,6-lutidine in a mixture of water and acetonitrile (MeCN) for 4 days at room temperature provided 16c in 62% yield. Scheme 1. Synthesis of phloroglucinol-based compounds 5a and 14a-c. H H H Reaction of 1,4,7-triazacyclononane (9) with propargyl bromide using a reported method 28 gave 17 along with quaternary ammonium salts due to over-alkylation (Scheme 3). By reducing the number of equivalents of propargyl bromide and controlling the reaction temperature during its addition, 17 was produced in 69% yield. The CuAAC reaction between 17 and azide 13 under the conditions used for preparation of 14a-c but without TBTA afforded compound 18 in 42% yield. Removal of copper ions from the crude product 18 was especially difficult, possibly due to metal ion chelation by the side arms and the 1,4,7-triazacyclononane core. It was necessary to remove the copper ions by extraction, 29,30 because preparative HPLC does not remove them. Fortunately, prolonged contact with dithizone in chloroform gave complete removal of the copper ions.
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Compounds 14a-c, 16a-c, and 18 used in biological assays were ≥95% pure as determined by HPLC analysis (see Electronic Supplementary Information). † Biological Assays. Using a new protocol (see the Discussion and the Experimental Section for details), saturation binding assays were performed using the known time-resolved fluorescence (TRF) probe, Eu-DTPA-PEGO-MSH(7)-NH 2 (19) 14,32 and HEK293 cells engineered to overexpress hMC4R (approximately 640,000 copies per cell) and human cholecystokinin 2 receptor (hCCK2R, approximately 1,100,000 copies per cell). 9 Saturation binding curves are depicted in Figure 1 . The K d for 19 calculated from these assays was 21 ± 3 nM, which is consistent with the value of 27 ± 4 nM reported from saturation binding assays using an older protocol. Competitive binding assays employed the new protocol, HEK293 cells engineered to overexpress hMC4R and hCCK2R, and the TRF probe 19. Representative binding curves are depicted in Figure 2 , and the results for all compounds are numerically summarized in Table 1 
Discussion
Previously we prepared MSH(4)-bearing multivalent molecules based on linear [21] [22] [23] [24] and spherical 25 scaffolds, most with inter-ligand distances in the 20-50 Å range. In competitive binding assays, these constructs generally exhibited the inhibitory potency of the MSH(4) ligand statistically amplified by the number of ligands present in the construct. In no case was potency clearly attributable to multivalent binding observed. Divalent and trivalent binding to hMC4 receptors was finally demonstrated by Brabez, et al., using the MSH(4)-bearing mono-, di-, and trivalent compounds 4-6. 18 The interligand distances in 5 and 6 were estimated to be 24 ± 5 Å by molecular modeling, suggesting that the limits on ligand spacing for multivalent binding to hMC4 receptors had been overestimated by the prior homology model, 20 at least for the engineered HEK293 cell line used in the competitive binding assays. To confirm this observation, we elected to pursue multivalent molecules based on the "disc-like" cores afforded by phloroglucinol (7), tripropargylamine (8) , and 1,4,7-triazacyclononane (9). These compounds have been used as cores for dendrimeric molecules 34-37 and in syntheses of multivalent molecules.
38-40
Their simplicity and commercial availability suggest synthetic versatility and economy, important considerations for implementation of a general strategy for ligand multimerization. The kind, number, and spacing of the ligands can easily be controlled, and in the case of trivalent molecules, the ligands would be prearranged in a trigonal planar fashion. In the event, assembly of 12a, 14a-c, 15a, 16a-c, and 18 by alkylations of 7 and 9 with propargyl bromide, followed by CuAAC attachment of the placeholder serinamide ligand 11 and/or the MSH(4) ligand 13 to trialkynes 8, 10, and 17 required short reaction sequences that were reasonably straightforward and efficient.
Standard high throughput TRF assays used to screen for functional binding are normally conducted with cells grown in 96-well plates (Costar 3603). 41, 42 In the present study with HEK293 cells, these assays exhibited relatively poor signal-tonoise ratios due to cell detachment during the multiple wash and reagent addition steps. The use of more adherent A375 cells bearing melanocortin 1 receptors 43 also gave poor signalto-noise ratios due to the lower receptor expression levels of these cells. While the engineered HEK293 cells express about 640,000 MC4 receptors per cell, 9 the A375 cells express about 75,000 MC1 receptors per cell. 43 To improve the signal-to-noise ratios of the assays to provide more robust data for calculation of binding and inhibition constants, we shifted the assays from 96-well plates to 6-well plates in order to work with much larger populations of cells in a given sample well. While the 96-well plates were seeded at 20,000 cells per well and grew to 90% confluence (~40,000-50,000 cells per well) over about three days, the 6-well plates were seeded at 240,000 cells per well and required five days to grow to 90% confluence (~1 × 10 6 cells per well). The significantly larger cell population meant that small losses of cells during assay manipulations would have a lesser effect on the repeatability of the TRF data. To minimize the loss of cells during binding assays, solutions were carefully added down the sides of the well walls. To reduce non-specific signal due to adherence of the probe to the wells, the cells were scraped from the wells after the binding incubation and transferred to micro-centrifuge tubes for post-assay processing. These changes led to a robust assay with high repeatability and reproducibility. 44 To test the consistency of a result from the new protocol in 6-well plates with a published result from a previous protocol in 96-well plates, a saturation binding assay was performed for the known TRF probe 19 14, 32 using the new protocol and HEK293 cells engineered to overexpress hMC4R and hCCK2R. 9 The K d for 19 calculated from this assay was 21 ± 3 nM, while the reported K d for 19 from use of the previous protocol was 27 ± 4 nM.
14 This level of agreement was taken as a validation of the new protocol.
In the competitive binding assays, control compounds 12a and 15a did not inhibit the binding and uptake 33 of the TRF probe 19 over the concentration range tested. The monovalent constructs 14a and 16a exhibited K i values consistent with monovalent MSH (4) binding (approximately 1 µM).
23
Impressively, the divalent constructs 14b and 16b exhibited K i values of 91 and 69 nM, respectively, 11-fold and 32-fold lower than the corresponding monovalent molecules 14a and 16a. These increases in potency are consistent with the 9-fold enhancement observed when 5 was compared to 4 using probe 19 14 and are indicative of divalent binding.
45
Compounds 14c and 16c possess three copies of MSH (4) with what were presumed to be appropriate inter-ligand spacings for trivalent binding, and yet these compounds exhibited only two-fold enhancements in potency when compared with the corresponding divalent compounds 14b and 16b. These results, attributable to statistical effects, stand in contrast with the 9-fold enhancement in potency observed for trivalent 6 (K i = 4.3 nM) compared to divalent 5 (K i = 37 nM) when competed against probe 19.
14 Trivalent compound 18 exhibited a K i of 25 nM, a value reasonably consistent with those of 14c (K i = 45 nM) and 16c (K i = 36 nM).
The possibility that these results might have been due to a limit to the dynamic range of the competitive binding assay was excluded by competing NDP-α-MSH (1) against probe 19. The K i observed for 1 using the 6-well plate binding assay was 3.2 ± 0.4 nM, 46 a value consistent with earlier observations in 96-well plate binding assays. Thus, the greater avidity of 6, i.e. its ability to bind trivalently, must be rooted in structural differences with 14c, 16c, and 18.
In the design phase of this work, the maximum inter-ligand distances for 6, 14c, 16c, and 18, as measured by the distances between the N-terminal nitrogen atoms of the histidine residues, were estimated to be 33, 33, 28, and 32 Å, respectively, assuming full extension of all chain segments. 47 To better address issues that concern structure and conformation, molecular dynamics studies were performed using Molecular Operating Environment (MOE).
48,49
Views of representative conformations of 6, 14c, 16c, and 18 are displayed in Figure 3 . Given a sufficiently long molecular dynamics run, the side arms of the C 3 symmetric molecules 14c, 16c, and 18 would display conformational equivalence. 50 However, at most points in time the spatial relationships between the ligands will vary. Over the 2 ns time courses of our molecular dynamics runs, the inter- ligand distances lay between 17.0-28.0 Å for compound 6, 19.5-24.5 Å for 14c, 16.5-21.0 Å for 16c, and 16.5-23.0 Å for 18. These distances are at the low end of the 24±5 Å range previously suggested for compound 6.
18
It is generally held that, like other melanocortin receptors, MC4R forms constitutive dimers on the cell surface. 51 If a third MC4 receptor approaches, a trimer may form, but it need not be symmetrical. If the trimer is asymmetric, different inter-ligand distances may be required in order to simultaneously bridge to three ligand binding sites. Since the ligand binding sites of dimeric MC4Rs can be bridged by any of the divalent or trivalent molecules we have studied here, it seems reasonable to postulate that an optimum distance lies between 17 and 23 Å. Furthermore, we postulate that while compound 6 has sufficient "reach" to permit binding to a more remote third ligand binding site of a receptor trimer, compounds 14c, 16c, and 18 are unable to do so.
Given the ready adaptability of the synthetic method we have described, we plan to examine these postulates by construction and testing of sets of divalent molecules with inter-ligand distances ranging from 17-23 Å and sets of trivalent molecules possessing the optimal short inter-ligand distance and one longer inter-ligand distance (from the optimal short distance to 32 Å).
Additionally, assuming the order of magnitude difference in avidity afforded by divalency is sufficient for distinguishing healthy from abnormal cells by discernment of receptor overexpression, medically useful compounds might result from attachment of imaging or therapeutic agents to scaffolds derived from 7-9. We plan to pursue this line of investigation by replacement of the serinamide in 14b and 16b with radiolabels and fluorescent tags for use in in vitro saturation binding and uptake studies and in vivo imaging studies. 18 preparative HPLC column. A linear gradient of mobile phase was used over 45 min from 0-90% MeCN/water containing 0.1% TFA. The flow rate was 10 mL/min and a dual channel UV detector was used at 230 and 280 nm. Analytical HPLC was performed on a 3.0 × 150 mm Waters XBridge 3.5 µm C 18 analytical HPLC column. A linear gradient of mobile phase was used over 30 min from 10-90% MeCN/water containing 0.1% TFA. The flow rate was 0.3 mL/min and a dual channel UV detector was used at 220 and 280 nm. A VWR SympHony pH meter (Model SB20) equipped with a Ag/AgCl electrode was used for pH measurements. ESI experiments were performed on a Bruker 9.4 T Apex-Qh hybrid Fourier transform ion-cyclotron resonance (FT-ICR) instrument using standard ESI conditions. The samples were dissolved in MeCN/water 1:1 containing 0.1% formic acid in a concentration range of 1-30 µM. Optical rotations were measured on a Rudolph Research Autopol III polarimeter using a 50 mm sample cell (1 mL volume). Engineered HEK293 cells 9 overexpressing both hMC4R and hCCK2R were used to measure the affinity of the probe for binding to hMC4R by means of saturation binding assays. Unless otherwise specified, all cell incubations were done in a Fisher Scientific Isotemp CO 2 incubator (Model 3530) maintained at 37 °C and 5% CO 2 atmosphere. Europium-based time-resolved fluorescence (TRF) competitive binding assays were employed to study the binding of all multivalent constructs and controls. The probe used for binding assays, Eu-DTPA-PEGO-MSH(7)-NH 2 (19) , was prepared by a published procedure.
32
Centrifugations were performed on a VWR Galaxy 7 microcentrifuge or a Fischer Scientific Model 59A microcentrifuge. TRF was measured using a VICTOR X4 2030 Multilabel Reader (PerkinElmer) employing the standard Eu TRF measurement settings (340 nm excitation, 400 µs delay, and emission collection for 400 µs at 615 nm). Solid phase synthesis. NDP-α-MSH (1) and the MSH(4) derivative azide 13 were synthesized manually via an N α
-400 mesh, 0.68 mmol/g loading) was used for the synthesis of 13. Resin (1 g) was allowed to swell in THF for 1 h in a polypropylene syringe equipped with a polypropylene frit. THF was removed, a solution of 20% piperidine in DMF (15 mL) was added, and the tube was shaken for 2 min. This solution was removed, 20% piperidine in DMF (15 mL) was again added, and the mixture was shaken for another 18 min. After removal of the solution, the resin was washed sequentially with DMF (3 × 15 mL), DCM (3 × 15 mL), DMF (3 × 15 mL), 0.5 M 1-hydroxybenzotriazole (HOBt) in DMF (15 mL), 0.5 M HOBt in DMF + a drop of 0.01 M bromophenol blue solution in DMF (15 mL), DMF (2 × 15 mL), and DCM (15 mL) in that order. The amino acid (3 eq) to be coupled was activated by reaction in DMF (15 mL) in a glass vial with 1-hydroxy-6-chlorobenzotriazole (Cl-HOBt, 3 eq) and diisopropyl carbodiimide (DIC, 6 eq) over two min. This solution was then added to the resin and the syringe shaken for 1 h. The coupling solution was removed and the resin was washed with DMF (3 × 15 mL), DCM (3 × 15 mL), and DMF (3 × 15 mL). Free amine groups were capped by shaking the resin with acetic anhydride/pyridine (1:1, 6 mL) for 20 min. The resin was washed with DMF (3 × 15 mL), DCM (3 × 15 mL), and DMF (3 × 15 mL). The coupling cycle was then repeated for each of the remaining amino acids in the sequence. The Kaiser test 52 was used to determine coupling completion at each attachment step.
For the synthesis of 1, half (approximately 0.12 mmol) of the resin-bound, side chain-protected Fmoc-NDP-α-MSH was treated as follows. A solution of 20% piperidine in DMF (8 mL) was added and the tube shaken for 2 min. The solution was removed, 20% piperidine in DMF (8 mL) was added, and the mixture shaken for 18 min. After the removal of the solution, the resin was washed sequentially with DMF (3 × 8 mL), DCM (3 × 8 mL), and DMF (3 × 8 mL). N-terminal acylation was accomplished by treatment with a mixture of acetic anhydride/pyridine (1:1, 1 mL) in DMF (2 mL) for 1 h. The resin was then washed with DMF (3 × 8 mL), DCM (3 × 8 mL), DMF (3 × 8 mL), THF (8 mL), and DCM (8 mL), then left to dry for 1 h.
For the synthesis of azide 13, the N-terminal histidine residue was acylated using activated 6-azidohexanoic acid (2.04 mmol) in 15 mL of DCM with Cl-HOBt (345 mg, 2.04 mmol, 3 eq) and DIC (512 mg, 4.08 mmol, 6 eq).
A cleavage cocktail (6 mL for 1 and 10 mL for 13 and) consisting of TFA, thioanisole, triisopropylsilane, and H 2 O (9.1:0.3:0.3:0.3) was added to the resin and the syringe was shaken for 4 h at rt. The solution was transferred to a 15 mL centrifuge tube and the resin washed with further aliquots of TFA (2 × 2 mL, 2 min). The combined TFA solutions were concentrated in the centrifuge tube under a stream of argon, and the product precipitated by the addition of cold ether (8 mL). The tube was centrifuged and the supernatant removed. The pellet was washed with cold ether (3 × 6 mL), air dried, dissolved in 1 M acetic acid, and lyophilized. The resultant solid was subjected to reversed-phase preparative HPLC, product-containing fractions combined, and the solutions lyophilized. 
NDP-α α α α-MSH (1).

MSH(4)
Azide (13). 24 Off-white solid; yield 72% (384 mg, 0.49 mmol); HRMS (FT-ICR) m/z calcd. for C
1,3,5-Tris(prop-2-yn-1-yloxy)benzene (10).
26,53 To a round bottomed flask purged with argon was added DMF (20 mL), propargyl bromide (80% in toluene, 8.020 mL, 72 mmol, 4.5 eq), and K 2 CO 3 (8.95 g, 64.8 mmol, 4.0 eq). A solution of phloroglucinol (7, 2.02 g, 16.0 mmol, 1.0 eq) in DMF (12 mL) was added at rt dropwise with stirring over 15 min. After 4 d the solids were removed by filtration and washed with DCM. The filtrate and washings were concentrated in vacuo to yield a reddish slurry. To this material was added DCM (100 mL) and the mixture washed with water (3 x 100 mL) and brine (2 x 100 mL). The resultant red organic layer was dried over sodium sulfate, filtered, and volatiles removed in vacuo to yield 4.1 g of a red slurry.
This material was subjected to column chromatography on silica gel 60 with a mobile phase of 20% ethyl acetate in hexanes. The product-containing fractions were combined, volatiles removed in vacuo, and the resultant solid recrystallized from hexanes to give 10 as an off-white solid. 
N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-6-azidohexanamide (11).
24
To a stirred solution of 6-azidohexanoic acid 54 (6.00 g, 36.2 mmol, 1.0 eq) and Nhydroxysuccinamide (4.73 g, 39.9 mmol, 1.1 eq) in CHCl 3 /DMF (9:1, 15 mL) was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (7.80 g, 39.9 mmol, 1.1 eq). The mixture was stirred under argon overnight at rt. Chloroform was removed under vacuum and the resultant liquid partitioned between 1 N HCl (50 mL) and ether (50 mL). The organic layer was washed with 1 N HCl (3 × 50 mL), 5% NaHCO 3 (2 × 50 mL), water (2 × 50 mL), and brine (2 × 50 mL). The organic layer was then dried using anhydrous sodium sulfate, filtered, and concentrated under vacuum to produce 3. To a solution of serinamide hydrochloride (3.30 g, 23.0 mmol, 1.1 eq) in DMF (50 mL) was added triethylamine (3.21 mL, 23.0 mmol, 1.1 eq). To the resultant white suspension was added the succinamide ester from above (5.32 g, 20.9 mmol, 1.0 eq) and the reaction mixture stirred overnight. Volatiles were removed under vacuum and the resultant slurry subjected to flash column chromatography using a mobile phase of 10% MeOH/CHCl 3 
6,6',6''-(4,4',4''-((Benzene-1,3,5-triyltris(oxy))tris(methylene))tris(1H-1,2,3-triazole-4,1-diyl))tris(N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)hexanamide) (12a
6,6'-(4,4'-(((5-(Prop-2-yn-1-yloxy)-1,3-phenylene)bis(oxy))bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)hexanamide) (12b)
. DMF and a microwave vial (0.5-2 mL) were purged with argon for 30 min. To the vial were added tris(alkyne) 10 (72.3 mg, 301 µmol, 1.0 eq), serinamide azide 11 (146.4 mg, 602 µmol, 2.0 eq), TBTA (99.2 mg, 187 µmol, 0.6 eq), and TACP (69.8 mg, 187 µmol, 0.6 eq) in that order. To this mixture was added 600 µL of argon-purged DMF, whereupon a green solution was obtained. Sodium ascorbate (40.8 mg, 206 µmol, 1.1 eq per TACP) was added in a single portion, and the solution color changed to a light brown. The walls of the vial were washed down with 400 µL of argonpurged DMF, the vial sealed, irradiated in a microwave reactor to maintain a temperature of 100 °C for 4 h. N-(1-Amino-3-hydroxy-1-oxopropan-2-yl)-6-(4-((3,5-bis(prop-2-yn-1-yloxy)phenoxy)methyl)-1H-1,2,3-triazol-1-yl) hexanamide (12c). DMF and a microwave vial (0.5-2 mL) were purged with argon for 30 min. To the vial were added tris(alkyne) 10 (292.7 mg, 1.22 mmol, 2.0 eq), serinamide azide 11 (148.2 mg, 609.1 µmol, 1.0 eq), TBTA (64.6 mg, 121.8 µmol, 0.2 eq), and TACP (45.4 mg, 121.8 µmol, 0.2 eq) in that order. To this mixture was added 600 µL of argon-purged DMF, whereupon a green solution was obtained. Sodium ascorbate (26.5 mg, 113 µmol, 1.1 eq per TACP) was added in a single portion, and the solution color changed to a light brown. The walls of the vial were washed down with 400 µL of argon-purged DMF, the vial sealed, and irradiated in a microwave reactor to maintain a temperature of 100 °C for 4 h. The reaction mixture was then cooled, volatiles removed in vacuo, and the residue subjected to flash column chromatography using DCM/MeOH/conc NH 4 5-((1-((6S,9R,12S)-12-((1H-Imidazol-4-yl)methyl)-1-amino-6-(((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-9-benzyl-1-imino-8,11,14-trioxo-2,7,10,13-tetraazanonadecan-19-yl)-1H-1,2,3-triazol-4-yl)methoxy)-1,3-phenylene)bis(oxy))bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(N-(1-amino-3-hydroxy-1-oxopropan-2-yl) hexanamide) (14a). To a microwave vial (0.2-0.5 mL) purged with argon were added 12b (28.2 mg, 38.8 µmol, 1.0 eq), MSH(4) azide 13 (48.5 mg, 61.9 µmol, 1.5 eq), TBTA (4.4 mg, 8.3 µmol, 0.2 eq), and TACP (3.1 mg, 8.3 µmol, 0.2 eq). To this mixture were added 150 µL of argon-purged DMF and sodium ascorbate (1.8 mg, 9.1 µmol, 1.1 eq per TACP). The vial walls were washed down with 50 µL of argon-purged DMF, the vial sealed, and irradiated in a microwave reactor to maintain a temperature of 100 °C for 4 h. Volatiles were removed in vacuo and the residue dissolved in H 2 O (50 mL). The aqueous solution was extracted with a solution of dithizone in chloroform (0.5 mM, 3 × 30 mL) and chloroform (2 × 30 mL). 6'-(4,4'-(((5-((1-(6-((1-Amino-3-hydroxy-1-oxopropan-2-yl)amino)-6-oxohexyl)-1H-1,2,3-triazol-4-yl)methoxy)-1,3-phenylene)bis(oxy))bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(N-((S)-1-(((R)-1-(((S)-1-(((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)hexanamide) (14b) . To a microwave vial (0.2-0.5 mL) purged with argon were added 12c (28.5 mg, 58.9 µmol, 1.0 eq), MSH(4) azide 13 (145.8 mg, 186.1 µmol, 3 eq), TBTA (13.1 mg, 24.8 µmol, 0.4 eq), and TACP (9.2 mg, 24.8 µmol, 0.4 eq). To this mixture was added 300 µL of argon-purged DMF and sodium ascorbate (5.4 mg, 27.3 µmol, 1.1 eq per TACP). The vial walls were washed down with 50 µL of argon-purged DMF, the vial sealed, and irradiated in a microwave reactor to maintain a temperature of 100 °C for 4 h. Volatiles were removed in vacuo and the residue dissolved in H 2 O (50 mL). The aqueous solution was extracted with a solution of dithizone in chloroform (1. 1H-1,2,3-triazole-4,1-diyl))tris(N-((S)-1-(((R)-1-(((S)-1-(((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)hexanamide) (14c) . To a microwave vial (0.2-0.5 mL) purged with argon were added MSH(4) azide 13 (87 mg, 111.1 µmol, 6.0 eq), TBTA (11.7 mg, 22 µmol, 1.2 eq), and TACP (8.2 mg, 22 µmol, 1.2 eq). To this mixture was added 125 µL (18.5 mol. 1.0 eq) of a solution of 10 in DMF (35.6 mg/mL). Sodium ascorbate (4.8 mg, 24 µmol, 1.1 eq per TACP) was added followed by 75 µL of argon-purged DMF. The vial was sealed and irradiated in a microwave reactor to maintain a temperature of 100 °C for 4 h. The reaction mixture was then cooled, volatiles removed in vacuo, and the residue dissolved in H 2 O (60 mL). The aqueous solution was extracted with a solution of dithizone in chloroform (0.5 mM, 3 × 30 mL) and chloroform (3 × 30 mL). The resulting yellow aqueous phase was lyophilized, giving 80 mg of residue. Preparative reversed phase HPLC gave 24.5 mg (9.5 µmol, 51%) of 14c as a fluffy white solid; HRMS (FT-ICR) m/z calcd. for C 129 H 165 N 42 O 18 [M+3H] 3+ 863.77661, found 863.77676; Analytical HPLC t R 13.41 min. 6',6''-(4,4',4''-(Nitrilotris(methylene))tris(1H-1,2,3-triazole-4,1-diyl))tris(N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)hexanamide) (15a) . Using the procedure outlined for 12a, compound 15a was prepared from 8 (28.9 µL, -2-yn-1-ylazanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)hexanamide) (15b) . Using the procedure outlined for 12b, compound 15b was prepared from 8 (59.2 µL, 410 µmol, 1.0 eq), serinamide azide 11 (200 mg, 820 µmol, 2.0 eq), TBTA (84.8 mg, 160 µmol, 0.4 eq), and TACP (59.6 mg, 160 µmol, 0.4 eq), sodium ascorbate (34.9 mg, 180 µmol, 1.1 eq per TACP), and DMF (2 mL 1-((6S,9R,12S)-12-((1H-Imidazol-4-yl)methyl)-1-amino-6-(((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamoyl)-9-benzyl-1-imino-8,11,14-trioxo-2,7,10,13-tetraazanonadecan-19-yl)-1H-1,2,3-triazol-4 yl)methyl)azanediyl)bis(methylene))bis (1H-1,2,3-triazole-4,1-diyl))bis(N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)hexanamide) (16a) . Using the procedure given for the synthesis of 14a, compound 16a was prepared from 15b (183 µL of a 0.41 M solution in DMF, 75 µmol, 1.0 eq), MSH (4) 6'-(4,4'-((((1-(6-(((S)-1-Amino-3-hydroxy-1-oxopropan-2-yl)amino)-6-oxohexyl)-1H-1,2,3-triazol-4-yl)methyl)azanediyl)bis(methylene))bis(1H-1,2,3-triazole-4,1-diyl))bis(N-((S)-1-(((R)-1-(((S)-1-(((S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-5-guanidino-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)hexanamide) (16b) . Using the procedure given for the synthesis of 14b, compound 16b was prepared from 15c (120 µL of a 0.50 M solution in DMF, 60 µmol, 1.0 eq), MSH (4) -2-yn-1-yl)-1,4,7-triazonane (17) . 28 To a stirred solution of 1,4,7-triazacyclononane hydrochloride (9, 250 mg, 1.02 mmol, 1.0 eq) in toluene/ethanol (1:1, 5 mL) was added potassium hydroxide (355 mg, 6.3 mmol, 6.3 eq). After 30 min, the flask was cooled in an ice-water bath and propargyl bromide (80% in toluene, 0.317 mL, 2.13 mmol, 2.1 eq) was added dropwise as a solution in toluene/ethanol (1:1, 5 mL). The reaction mixture was allowed to attain rt and was stirred for 24 h. The resultant suspension was filtered to remove the solid matter and volatiles removed in vacuo to give a brownish solid. Flash chromatography on silica gel initially buffered with 1% triethylamine in hexanes using MeOH/DCM/conc NH 4 OH (0.5:9.5:0.05) as the eluent afforded 171 mg (0.70 mmol, 69%) of 17 as a yellowish oil which solidified upon standing overnight; R f 0.38 (MeOH/DCM/conc NH 4 
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Biological Assays
Preparation of Solutions. Stock solutions of the MSH(4) constructs 14a-c, 16a-c, and 18, control compounds 12a and 15a, and the Eu-DTPA-PEGO-MSH(7)-NH 2 probe (19) were made up in DMSO at a nominal concentration of 2.0 mM based on measured weights of solutes. Except for the control compounds, concentrations were refined by comparison to a DTrp standard solution (0.50 mM) using analytical HPLC. Selective growth media for cell growth was prepared by supplementing Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum, 1% penicillin-streptomycin, 0.1% zeocin, and 0.8% geneticin. Basic buffer was prepared by dissolving 5.97 g of 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) and 2 g BSA in 1 L of DMEM. The pH of this solution was adjusted to 7.4 using 2 N NaOH and the solution sterilized by filtration through a 0.22 µm filter (Corning, 431117, 500 mL bottle-top filter, sterile) under vacuum. Binding buffer was prepared by supplementing DMEM (1 L) with HEPES (5.97 g), BSA (2 g), 1,10-phenanthroline (1 mL of a 1 M solution in EtOH), leupeptin (1 mL of a 500 mg/L aqueous solution), and bacitracin (1 mL of a 200 g/L aqueous solution). The pH of this solution was adjusted to 7.4 using 2 N NaOH and the solution sterilized by filtration through a 0.22 µm filter (Corning, 431117, 500 mL bottle-top filter, sterile) under vacuum.
Cell Culture. Dual (MC4R/CCK2R) expressing HEK293 cells 9 were maintained in selective growth media. For the binding assays, cells were plated into 6 well plates (Greiner Bio-One, 657160, Cell Culture Multi-well Plates, Polystyrene, 6 wells) at 240,000 cells per well in a total volume of 3 mL (2 mL of the selective growth media added initially to each well, followed by 1 mL of cell suspension). On the third day after plating, additional selective growth media (1 mL) was carefully added to each of the wells so as not to disturb the cells. The cells were left to grow until ~90% confluence was achieved (usually by day 5) before conducting assays. Saturation Binding Assays. Six solutions containing both the probe Eu-DTPA-PEGO-MSH(7)-NH 2 (19) and NDP-α-MSH (1) were made in 1.2 mL of binding buffer in separate microcentrifuge tubes (one per each well). All six tubes contained 1 µM concentrations of NDP-α-MSH (1), while the concentration of the probe 19 was varied across the six tubes (1, 10, 25, 50, 100, 250 nM). These six solutions were used to assess nonspecific binding. A second set of six solutions (1.2 mL each) contained the probe 19 at the same concentrations without NDP-α-MSH. These solutions were used to assess total binding.
To commence an assay, cell-containing 6-well plates (× 2) were removed from the incubator and the selective growth media removed by careful aspiration. The twelve prepared solutions detailed above were carefully transferred (1 mL per well) by pipette down the well walls (to minimize disturbance of the cells, which can result in cell loss during media exchanges). The plates were then maintained in a CO 2 incubator at 37 °C for 1 h.
Solutions were then removed by careful aspiration and 600 µL of basic buffer were added to each well. The cells were scraped from each well individually using a Cell Scraper (18 cm, GeneMate) and transferred in suspension to separate 1.7 mL micro-centrifuge tubes. The wells and scraper were rinsed with 600 µL of basic buffer and the rinses combined with the corresponding suspension. One scraper was used across the wells measuring total binding, and another was used across the wells measuring non-specific binding.
The tubes containing the cell suspensions were centrifuged (3000 rpm for 3 min) in a micro-centrifuge. After removing the supernatant, the cells were resuspended in basic buffer (1 mL) and incubated for 5 min in a 37 °C water bath during each of three wash cycles. After the final wash, 600 µL of DELFIA Enhancement Solution (Perkin Elmer 1244-104) was added to each cell pellet, the tubes mixed using a vortex mixer, and incubated for 1 h in a water bath maintained at 37 °C.
Following the incubation, cells and cell fragments were pelleted (5000 rpm for 5 min) and 4 × 100 µL aliquots of each supernatant were transferred to a 96 well plate (Perkin-Elmer, 6005060, tissue culture treated B&W Isoplate-96) for fluorescence measurement using a VICTOR X4 2030 Multilabel Reader.
Competitive Binding Assays. Immediately before an assay, twelve solutions (1350 µL each) of compounds to be tested were made up in binding buffer in microcentrifuge tubes at concentrations ranging from 10 µM-0.10 nM. Each of the tubes also contained the Eu-DTPA-PEGO-MSH(7)-NH 2 probe 19 at a concentration of 20 nM. Cell-containing 6-well plates (× 2) were removed from the incubator and the selective growth media removed by careful aspiration. The twelve prepared solutions from above were carefully transferred (1 mL per well) by pipette down the well walls. The plates were then maintained in a CO 2 incubator at 37 °C for 1 h.
After 1 h, solutions were removed by careful aspiration and 600 µL of basic buffer were added to each well. The cells were scraped from each well using a Cell Scraper (18 cm, GeneMate) and transferred in suspension to separate 1.7 mL micro-centrifuge tubes. The wells and scraper were rinsed with 12 | J. Name., 2012, 00, [1] [2] [3] This journal is © The Royal Society of Chemistry 2012 600 µL of basic buffer and the rinses combined with the corresponding suspension. The cell suspensions were centrifuged (3000 rpm for 3 min) in a micro-centrifuge. After removing the supernatant, the cells were resuspended in basic buffer (1 mL) and incubated for 5 min in a 37 °C water bath during each of three wash cycles. After the final wash, 600 µL of DELFIA Enhancement Solution (Perkin Elmer 1244-104) was added to each cell pellet, the tubes mixed using a vortex mixer, and incubated in a water bath maintained at 37 °C for 1 h.
Data Analysis. NMR data were analyzed using MestReNova (Mestre Lab Research S. L., version 7.1.1) software. Biological data analysis was performed using GraphPad Prism software (version 5.04). A description of the binding equations used appears in the Electronic Supplementary Information.
Conclusions
We have demonstrated short and efficient syntheses of multivalent molecules targeted to melanocortin receptors based on three commercially available trigonal core scaffolds. This methodology can be adapted to prepare asymmetric constructs involving two and possibly three different ligands, or combinations of one or two ligands with reporters and/or therapeutic agents. Pertaining to MC4R, we have obtained evidence that the proper ligand spacing for multivalent binding to dimeric receptors is in the short end of the previously reported range, 24±5 Å.
